
He’s Off Mealtime Insulin: Here’s His Tzield Story
Send us Fan Mail What if a newly diagnosed person with type 1 diabetes (T1D) could dramatically reduce their insulin needs, or even stop taking mealtime insulin altogether? In this episode of the Diabetes Nerd Podcast, we sit down with Jacob, who was diagnosed with T1D in February 2026 and enrolled in the Beta Preserve clinical trial just weeks later. The study is exploring whether two rounds of Tzield (teplizumab) can preserve insulin-producing beta cells more effectively than a single treatment. Just months after beginning treatment, Jacob has cut his basal insulin by more than half and no longer needs mealtime insulin. He shares what it was like to undergo 12 consecutive days of Tzield infusions, the side effects he experienced, and how his blood sugars and daily life have changed. We also discuss how Tzield works, why early screening for type 1 diabetes is becoming increasingly important, and what this research could mean for the future of T1D treatment. Most importantly, Jacob explains why he hopes his story inspires others to consider screening, clinical trials, and opportunities to preserve beta cell function after diagnosis. If you live with type 1 diabetes, care for someone who does, or want to stay informed about the latest diabetes research, this is an episode you won't want to miss. Would you consider participating in a clinical trial like this? Have questions about Tzield or T1D screening? Leave a comment. We'd love to hear your thoughts. Thanks for tuning in!
Publisher
Diabetes Nerd
Published
July 2, 2026
Duration
47 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Diabetes Nerd
@diabetesnerd
#hesoffmealtime #heres #tzield #medicine #selfimprovement
